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Abstract
Background: Despite the latest World Health Organization guidelines advocating daily therapy in HIV-TB
co-infected individuals, there are few recent studies comparing outcomes of thrice-weekly anti-tuberculosis
treatment in HIV-positive and HIV-negative patients with TB. The present study sets out to compare TB treatment
outcomes in these two groups in the Indian national programme, which currently involves thrice-weekly therapy
for all, regardless of HIV status.
Methods: HIV-positive and HIV-negative were consecutively screened for enrolment into this prospective
observational study, carried out at the All India Institute of Medical Sciences hospital, New Delhi, India, between
2006 and 2010. Patients were given short-course thrice-weekly rifampicin-based therapy, with all HIV-positive
patients being started on highly active antiretroviral therapy at least 14 days after commencing TB treatment.
Patients were regularly followed-up for 24 months after completion of treatment.
Results: 150 HIV-positive, 155 HIV-negative patients were enrolled consecutively for the study. Significantly higher
treatment success (93.5% vs. 76.7% at end of treatment, p < 0.001) and lower mortality (2.8% vs. 21.6% on follow up,
p < 0.001) were observed in HIV-negative patients. No significant difference was found in treatment failure
(p = 0.16), sputum smear (p = 0.58) and culture conversion (p = 0.55), and non-serious adverse event incidence
(p = 0.851) between the two groups. Low baseline CD4 cell count (<100 cells/ mm3) was the only predictor of
mortality in HIV-TB patients (odds ratio 8 · 43, p = 0 · 013).
Conclusions: Thrice-weekly anti-tuberculosis therapy is more effective in HIV-negative than in HIV-positive patients.
However, outcomes in this HIV co-infected cohort were found to be similar to those reported previously with daily
therapy, with no safety concerns. This should prompt further study into whether intermittent or daily therapy
should be used universally in resource-poor settings, using large well executed randomised controlled trials.
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Keywords: Antitubercular agents/therapeutic use, Tuberculosis/drug therapy, Mortality, HIV infections/complications,
Treatment outcome
* Correspondence: sksharma.aiims@gmail.com
1Department of Medicine, All India Institute of Medical Sciences, Ansari
Nagar, New Delhi 110029, India
Full list of author information is available at the end of the article
© 2013 Vashishtha et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Vashishtha et al. BMC Infectious Diseases 2013, 13:468
http://www.biomedcentral.com/1471-2334/13/468
Background
Tuberculosis (TB) and human immunodeficiency virus
(HIV) infection are leading causes of morbidity and morta-
lity worldwide [1,2]. Despite significant progress in TB con-
trol in recent years [3], the HIV epidemic has posed a
substantial challenge in the form of HIV and TB co-
infection [3-5]. There is much debate over how anti-
tuberculosis therapy (ATT) should be administered to such
individuals, given their immunocompromised state, poten-
tial for drug-drug interactions [6,7], higher mortality rates
[1-4,8-10] and differences in presentation and organ in-
volvement [3,6,7]. Some areas are widely agreed upon, such
as modification of antiretroviral therapy (ART) to avoid
interactions [3,4,6,7], ATT commencing before ART in
treatment-naïve patients [3,6], and avoidance of once- or
twice-weekly dosing schedules [2,3,6,11]. However, specific
issues which are being increasingly debated and researched
include optimal duration of therapy [3,6-8,11-15], use of
daily versus intermittent regimens (WHO recommend daily
in at least the intensive phase) [3,15,16], and optimal timing
of ART commencement [2,3,5-7].
A recent meta-analysis by Khan and colleagues sug-
gests that there is a relative lack of high quality data on
outcomes of ATT in HIV-TB co-infected patients, espe-
cially with regards to intermittent dosing schedules [16].
When comparing daily and thrice-weekly therapy, the
comparative meta-analysis included over 3000 patients
who had received daily treatment in the intensive phase,
but only 211 who were treated with thrice-weekly regi-
mens [16]. There are many studies reporting outcomes
of ATT in HIV-infected patients with sputum smear and
culture positive pulmonary TB [2,10,13-15,17-19] but
few including smear-negative and extrapulmonary TB
[8,9,11,12]. In the real-world, co-infected individuals are
much more likely to have these challenging forms of TB
[1,3], thus highlighting lacunae in research.
It is our personal observation that TB treatment using
the current Indian national guidelines, which, in line
with the previous WHO guidance, advocate 6-month
thrice-weekly ATT irrespective of HIV status, outcomes
are poorer in HIV-infected individuals. Hence, an obser-
vational study was undertaken to compare outcomes
of current TB treatment in ATT- and ART-naïve HIV-
positive and HIV-negative patients.
Methods
Study design and case selection
This prospective observational study was conducted at
the All India Institute of Medical Sciences hospital, a
large tertiary centre in New Delhi, northern India. The
Department of Medicine provides specialist TB and HIV
services to Delhi and neighbouring states. All socio-
economic strata are represented, but the majority are in
lower groups [20].
ATT and ART naïve patients aged 18–65 years receiving
a new diagnosis of active TB between April 2006 and
October 2010, were consecutively assessed for enrolment.
The following exclusion criteria were applied: patients
with previous history of TB, ATT or ART; pregnant, lac-
tating and seriously unwell patients; those with signi-
ficantly raised serum transaminase levels or concomitant
renal impairment, liver failure, diabetes mellitus, epilepsy
or alcoholism; patients with hepatitis B or C virus co-
infection; those unable to attend follow-up; and any
patient having been on ATT for more than two weeks du-
ring the current schedule.
Two groups were formed: one with ART-naive patients
having a new or existing diagnosis of concurrent HIV
infection, and HIV-negative patients in the other. The
All India Institute of Medical Sciences Institute Ethics
Committee approved the study, and written informed
consent was obtained from patients.
Diagnosis and baseline assessment
All patients were counselled and tested for HIV using a
licensed third generation ELISA kit as described previ-
ously [20]. TB was diagnosed using investigations as
indicated and possible. These included Ziehl Neelson
smear microscopy followed by Lowenstein Jensen cul-
ture of sputum and any body fluids, secretions, tissue or
pus; Mycobacterium tuberculosis polymerase chain reac-
tion (PCR); histo- and cytopathological examination of
tissue or fluid (including broncho-alveolar lavage if
required); and various imaging modalities. For example,
all subjects with suspected pulmonary TB underwent
sputum or broncho-alveolar lavage smear and culture,
whereas if fluids such as cerebrospinal fluid and pleural
aspirate were smear negative, then M. tuberculosis PCR
was performed.
TB diagnosis in suspected cases was classified as
definitive (diagnosed by smear, culture or PCR) or
probable (clinical and radiological response to treat-
ment and suggestive radiology, histology, cytology or
fluid biochemistry) [21].
All patients underwent baseline clinical assessment,
chest radiography and blood tests, including CD4 lym-
phocyte count by flow cytometry (Becton Dickinson,
USA). Plasma viral load estimation was performed in
HIV-infected individuals, using either semi-quantitative
(Amplicor HIV-1 Monitor Test, Roche, Indianapolis) or
real time PCR methods. In pulmonary TB, chest radio-
graphic severity was graded [22]. In smear-positive pa-
tients, the sputum smear bacillary load was graded as
scanty, 1+, 2+ or 3+ as per WHO guidelines [23].
Treatment
Thrice-weekly rifampicin-based directly observed ATT
was given as per the Indian Revised National TB Control
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Programme guidelines [24]. This involved two months of
thrice weekly isoniazid (600 mg), rifampicin (450 mg; 600
mg if weight > 60 kg), pyrazinamide (1500 mg) and etham-
butol (1200 mg) [intensive phase], and four months of
thrice weekly isoniazid and rifampicin (doses as above)
[continuation phase] [24].
Extension of ATT was considered in patients who
showed clinical and/or radiological signs of disease progres-
sion or partial response, or persisting sputum smear posi-
tivity at the end of the intensive phase, after a consensus
decision by two or more investigators. The extensions were
of one, two or three months, of either the intensive (one
month) or continuation phase (maximum three months). If
despite extension, a patient was still deemed to have incom-
plete response at the end of treatment, this was labelled as
treatment failure. They were started on 'category II' ATT as
per the national guidelines (i.e. longer therapy with strepto-
mycin added) [24], subsequently guided by susceptibilities
from susceptibility testing results.
All HIV-positive patients received free highly active
ART as per India’s National AIDS Control Organisa-
tion guidelines: lamivudine (150 mg q12h) and efavi-
renz (600 mg qd) with either zidovudine (300 mg
q12h, in those with haemoglobin >8 g/dl) or stavudine
(30 mg q12h, if Hb <8 g/dl), which was started two
weeks or more after commencement of, but during,
ATT [25]. After completion of ATT, efavirenz was re-
placed with nevirapine (200 mg q12h) [25]. All HIV-
infected patients diagnosed in 2008 or later were
started on prophylactic co-trimoxazole therapy as per
changes in national guidelines [25]. Of those diag-
nosed before 2008, all with CD4 count <200 cells/mm3
received prophylaxis.
Follow-up
Follow-up was fortnightly during the first two months
of treatment, subsequently monthly up to the end of
ATT, then at 3, 6, 12, 18 and 24 months post-ATT.
Follow-up, using a structured pro forma document, in-
cluded clinical assessment, monitoring for opportunistic
infections (in HIV-positive patients), routine blood in-
vestigations, sputum smear and culture if appropriate
and possible, and repeat imaging as at enrolment to
monitor response to treatment.
In pulmonary TB patients, monthly chest radiographs
and fortnightly sputum smear and culture were performed.
CD4 cell counts were measured at enrolment and 6
months after starting treatment in all, with subsequent
six-monthly counts in HIV-positive patients only. Plasma
viral loads were measured at baseline, 6 months after com-
mencing ATT, and then after a further 6 and 24 months
in the HIV-positive group.
Adherence to treatment was checked at each visit to
the DOTS (thrice weekly in the intensive phase, weekly
thereafter) or ART centre (monthly) by questioning and
blister pack checks. These were supported by a medical
social worker.
Adverse events observed were noted and communi-
cated to the principal investigator and ethics committee.
These were classified as non-serious and serious adverse
events. The former included mild and moderate events
such as nausea, abdominal pain and itch; whereas im-
mune reconstitution inflammatory syndrome, new onset
anaemia, deaths and other severe or life-threatening
events were labelled as serious.
Mycobacterium tuberculosis genotyping was performed
with a spoligotyping commercial kit (Ocimum Bioso-
lutions Ltd., Hyderabad, India) according to a previously
described method, on relapse samples and correspon-
ding baseline samples, to differentiate exogenous re-
infection from endogenous reactivation [26].
Endpoints
The primary endpoint was outcome at the end of initial
treatment, as defined by the WHO: cure (smear- and
culture-negativity at end of treatment in smear-positive
pulmonary TB), treatment completed (no evidence of
treatment failure or cure), treatment failure (smear- or
culture-positivity in the last 2 months of treatment, or evi-
dence of clinical and/or radiological worsening or partial
response), or death [3]. The term ‘treatment success’ refers
to the sum of ‘cure’ and ‘treatment completed’, and was
used as the main comparative outcome, due to the inclu-
sion of smear-negative and extrapulmonary cases in whom
the ‘cure’ label cannot be applied.
Secondary endpoints were treatment outcome at the
end of 24-month follow-up; duration of initial treatment;
sputum smear- and culture-conversion rate in sputum-
positive pulmonary TB patients; adverse events; and
mortality in HIV-co-infected patients.
Statistical analysis
Sample size calculation was as follows: an initial sample
of 165 patients would be required in each group would
be sufficient to detect a difference in treatment success
of 15% (HIV negative = 85%, HIV positive = 70%, with
two sided 5% significance level and 90% power), assum-
ing 25% attrition. Primary analysis was by modified
intention to treat, with on-treatment analysis for ad-
verse events. All patients receiving at least one dose of
ATT were included for treatment outcome analysis.
Comparisons between groups were analysed using Fish-
er’s exact or Pearson chi-squared tests for categorical
data, and unpaired t-test or Wilcoxon Rank-sum test
for qualitative characteristics. Odds ratios were calcu-
lated for independent risk factors for mortality in the
HIV-positive group. All analysis was carried out using
Stata® version 11.




305 patients were enrolled from the 497 consecutively
screened for eligibility; 155 were HIV-negative and 150
tested positive for HIV (Figure 1). End of treatment
outcomes underwent modified intention to treat ana-
lysis: all patients undergoing any treatment were in-
cluded. Follow-up based outcomes, also undergoing
modified intention to treat analysis, included all except
those still under regular follow-up (n = 211). In the con-
text of adverse events, on treatment analysis was applied
to all those receiving any ATT (n = 305).
Baseline characteristics for the two groups are com-
pared in Table 1. Body mass index and serum bilirubin
were not found to differ significantly. Foci of TB involve-
ment in each group are shown in Table 2. Extra-
pulmonary involvement (p = 0 · 001) and dissemination
(p < 0 · 001) were significantly more common in patients
with HIV. For pulmonary TB patients, Tables 3 depicts
the baseline sputum smear results and chest radiograph
severity. The bacillary load was significantly higher in
HIV-negative than HIV-positive smear-positive patients
(P < 0 · 001).
The basis of diagnosis for each group is shown in
Table 4. Using the classification described above, 74
(49 · 3%) of the HIV-positive and 121 (78 · 1%) of HIV-
negative diagnoses were ‘definitive’. Of the 83 (27 · 2%)
‘radio-clinical’ cases (diagnosed on the basis of radio-
logical findings and clinical features), all but 11 of these
displayed full response to treatment – of those who did
not, six died, four were lost to follow-up during treat-
ment, and one failed treatment. Extensive attempts were
made to rule out other diagnoses.
End of treatment outcome
Treatment outcome at the end of ATT for each group is
detailed in Table 5. Treatment success was achieved in
76 · 7% of the HIV-positive and 93 · 5% of the HIV-
negative patients (p <0 · 001). There were nine HIV-
positive treatment failures; four in the HIV-negative
group (p = 0 · 16), of which six (two pulmonary) and four
(three pulmonary) were microbiologically confirmed,
respectively. One HIV-infected patient who failed initial
ATT, was well after re-treatment with a 'category II'
regimen, but later relapsed, and after the end of sche-
duled follow-up was diagnosed with multi-drug resistant
(MDR) pulmonary TB. One HIV-negative patient failed
the re-treatment regimen and was subsequently diag-
nosed as having MDR pulmonary TB.
Thirteen HIV-positive and two HIV-negative patients died
while on treatment (p < 0 · 01). Thirteen (four defaulters,
nine untraceable) HIV-positive patients were lost to follow-
up; as were four HIV-negative patients (all untraceable). One
patient with HIV had to have their treatment modified per-
manently due to isoniazid-induced psychosis.
A total of 35 (23 · 3%) HIV-positive patients required
extensions of ATT, whereas only 13 (7 · 8%) of the HIV-
negative patients had their ATT extended (p = 0 · 001).
Each group had a median additional duration of 1 month.
Comparison of baseline BMI and laboratory parame-
ters with those at 6 months of treatment is provided in
Table 6. Serum albumin and CD4 counts increased sig-
nificantly in HIV-positive patients.
Subgroup analysis was performed on initial treatment
outcomes of sputum smear-positive pulmonary TB pa-
tients with and without HIV co-infection, who had com-












Completed 24m follow-up: 52
Continuing follow-up: 48
(Total: 100)
Completed 24m follow-up: 79
Continuing follow-up: 46
(Total: 125)
Treatment not completed: 27
Death: 13
Lost to follow-up: 13
ATT modified: 1
Treatment not completed : 7
Death: 2
Lost to follow-up: 4
Started 2 nd line ATT: 1
Follow-up not completed: 23
Death: 1
Lost to follow-up: 17
Transfer due to relapse: 2
Transfer due to treatment failure: 3
Follow-up not completed: 23
Death: 9*
Lost to follow-up: 12
Transfer due to relapse: 1
Transfer due to treatment failure: 1
* A further 2 died who were already lost to 
follow-up before completing treatment
Figure 1 Study profile.
Vashishtha et al. BMC Infectious Diseases 2013, 13:468 Page 4 of 9
http://www.biomedcentral.com/1471-2334/13/468
(95 · 2%) in the HIV-negative group and 36 of 52 (69.2%)
HIV-positive patients had treatment success (p < 0 · 001).
Sputum smear (32/38 [84.2%] HIV+, 64/80 [80.0%] HIV-,
p = 0.58) and culture (29/34 [85.3%] HIV+, 71/88 [80.7%]
HIV-, p = 0.55) conversion proportions in sputum-positive
pulmonary patients at two months (up to 9 weeks) were
found to be similar among the two groups.
Follow-up
At the time of analysis, a total of 123/150 (82%) of the
HIV-positive and 148/155 (95 · 5%) HIV-negative patients had completed planned treatment of 6 to 9
months (Figure 1).
Table 8 shows treatment outcome at 24 months follow-
up (i.e. excluding patients under active follow-up, but
including deaths and loss to follow-up). The mean follow-
up time for HIV-positive and –negative patients was
14 · 1 ± 8 · 73 months and 17 · 8 ± 7 · 80 months,






Age 34.2 ± 8.3 27.2 ± 9.5 <0.001
Gender (M:F, %) 83:17 58:42 <0.001
BMI (kg/m2) 18.1 ± 2.8 17.9 ± 3.6 0.48
Haemoglobin (g/dL) 10.0 ± 2.2 11.1 ± 1.8 <0.001
Erythrocyte sedimentation
rate (mm/hr)
49.4 ± 23.6 43.7 ± 21.4 0.03
Absolute lymphocyte
count (/mm3)
2071 ± 1010 2435 ± 938 0.001
CD4 count (/mm3) 194 ± 167 593 ± 232 <0.001
Albumin (g/dL) 3.5 ± 0.7 4.2 ± 0.6 <0.001
Bilirubin (mg/dL) 0.65 ± 0.24 0.67 ± 0.16 0.48
Alanine aminotransferase
(IU/L)
53.7 ± 42.5 39.2 ± 21.9 <0.001
Aspartate aminotransferase
(IU/L)
48.2 ± 70.3 32.7 ± 21.0 <0.01
Uric acid (units) 5.7 ± 2.7 5.1 ± 1.5 <0.01
Viral load (log copies/mL) 5.23 (4.74-5.76)
Mean +/− standard deviation except median (inter-quartile range) in viral load.







Pulmonary TB 89 (59.3%) 119 (76.8%) 208 (68.2%)
Pulmonary only 49 (32.7%) 111 (71.6%) 160 (52.5%)
Miliary 2 (1.3%) 2 (1.3%) 4 (1.3%)
Disseminated* 38 (25.3%) 6 (3.9%) 44 (14.4%)
Extrapulmonary TB 61 (40.7%) 36 (23.2%) 97 (31.8%)
Lymph node 35 (23.3%) 23 (14.8%) 58 (19.0%)
Pleural 5 (3.3%) 4 (2.6%) 9 (3.0%)
Intestinal 0 1 (0.6%) 1 (0.3%)
Genitourinary 0 1 (0.6%) 1 (0.3%)
Peritoneal (ascites) 0 1 (0.6%) 1 (0.3%)
Disseminated* 21 (14%) 6 (3.9%) 27 (8.9%)
* Dissemination was defined as involvement of two or more non-contiguous
organ sites [27]. Patients were labelled as ‘pulmonary, disseminated’ in case of
presence of concomitant pulmonary and distant extrapulmonary disease, or
‘extrapulmonary, disseminated’ if there was evidence of dissemination without
any lung parenchymal involvement.
Table 3 Baseline sputum smear and culture results for
pulmonary TB patients







Negative 24 (27.0%) 9 (7.6%) 33 (15.9%)
Unable to produce sputum 19 (21.3%) 7 (5.9%) 26 (12.5%)
Total positive 46 (51.6%) 103 (86.6%) 149 (71.6%)
Scanty 8 (17.4%) 4 (3.9%) 12 (8.1%)
1+ 22 (47.8%) 24 (23.3%) 46 (30.9%)
2+ 6 (13.0%) 25 (24.3%) 31 (20.1%)
3+ 8 (17.4%) 50 (48.5%) 58 (38.9%)
Grading unavailable (Positive) 2 (4.3%) 0 2 (1.3%)
Culture results
Negative 24 (27.0%) 5 (4.2%) 29 (13.9%)
Unavailable+ 24 (27.0%) 10 (8.4%) 34 (16.3%)
Positive 41 (46.1%)* 104 (87.4%)* 145 (69.7%)
Chest radiograph severity†
No infiltrates 10 (11.2) 2 (1.7) 12 (5.8)
Minimal lesions 25 (28.1) 27 (22.7) 52 (25.0)
Moderately advanced 38 (42.7) 61 (51.3) 99 (47.6)
Far advanced 16 (18.0) 29 (24.4) 45 (21.6)
* One HIV-negative patient was smear-negative, culture-positive; four
HIV-positive patients were smear-positive but culture negative, and one
HIV-positive individual was smear-positive, but their culture result was not
available.
+ This includes those unable to produce sputum despite sputum induction
(see 'smear results' section of Table 3), as well as those whose sputum culture
results were not available for other reasons.
† According to the National Tuberculosis Association of the USA classification
[22].
Table 4 Basis of diagnosis of TB






Smear/culture+ 70 (46.7) 120 (77.4) 190 (62.3)
PCR+ 4 (2.7) 1 (0.6) 5 (1.6)
Cyto-/Histopathology 11 (7.3) 15 (9.7) 26 (8.5)
Chemistry (raised fluid
ADA levels)
0 1 (0.6) 1 (0.3)
Radio-clinical 65 (43.3) 18 (11.6) 83 (27.2)
+ Constitute definitive diagnosis.
N.B. in case of more than one diagnostic criterion being suggestive of TB,
that with highest value was taken, in the order: smear/culture > PCR > cyto-/
histopathology > chemistry > radio-clinical.
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respectively. Attrition rates were 24.5% in the HIV-
positive group, and 19.3% of HIV-negative patients, des-
pite attempts (telephone, home visits) to find those who
were lost to follow-up.
Uni- and multivariate analysis of independent va-
riables found no predictor of unfavourable outcome
(i.e. any outcome other than treatment success) in the
two groups. Variables included various blood test re-
sults at baseline (erythrocyte sedimentation rate, serum
albumin, haemoglobin, CD4 cell count), chest X-ray se-
verity, sex, age, presence of dissemination of TB, body
mass index, and whether the TB was pulmonary or
extrapulmonary.
The median time of relapse after treatment was six
months. Relapse rate in percentage per person year ob-
served (PYO) was calculated: in HIV-positive patients,
3 · 48% PYO (95% confidence interval [CI]: 0 · 43-6· 54%),
and 0 · 91% PYO (CI: 0 · 35-2 · 18%) in HIV-negative pa-
tients [p = 0 · 09]. Of the five HIV-positive relapses, three
were pulmonary; the two HIV-negative patients both
suffered pulmonary relapses. Of the four HIV-positive
pulmonary TB patients, 3 had different spoligotyping ge-
notypes suggesting exogenous re-infection while one had
similar genotype suggesting endogenous reactivation. One
patient in the HIV-negative group had similar genotype.
HIV-specific outcomes
Of the HIV-positive patients, all but one were started on
highly active ART (one died before commencement). The
median interval between starting the ATT and ART was
30 days (interquartile range: 17–60 days). Zidovudine-
based therapy was given to 65%, the remaining 35%
(53/150) received stavudine.
Mean rise in CD4 cell count and median fall in log
plasma HIV viral load over the TB treatment phase were
statistically significant (P < 0.001).
Co-trimoxazole prophylaxis was given in 134/150
(89 · 3%). Fourteen patients were found to have oppor-
tunistic infections other than TB, some with multiple in-
fections. The majority of these were present at baseline
assessment.








Treatment success+ 115 (76.7) 145 (93.5) <0.001
Treatment completed 85 (56.7) 45 (29.0)
Cure 30 (20.0) 100 (64.5)
Treatment failure 8 (5.3) 4 (2.6) 0.16
Default 4 (2.7) 0
Lost to follow-up 9 (6.0) 4 (2.6)
Death 13 (8.7) 2 (1.3) <0.01
Treatment modified 1 (0.7) 0
+ Sum of cure and treatment completed.
Table 6 Changes in various parameters between baseline
and 6 months of treatment
HIV+ HIV-
Parameter Pre Post Pre Post
BMI, mean, kg/m2 18.1 19.8 17.9 19.7
Haemoglobin, mean, g/dl 10.0 12.3 11.1 13.2
ESR, mean, mm/h 49.4 34.1 43.7 24.2
Albumin, mean, g/dl 3.5 4.3 4.2 4.7
CD4 cell count, mean, cells/mm3 194.1 330.8 593.2 676.5
HIV viral load, median, copies/ml 170339 400 - -
Bold type = statistically significant difference in degree of change between
the two groups (p < 0.05).
Table 7 Treatment outcome in smear-positive pulmonary
TB patients at end of initial ATT
TREATMENT OUTCOME
number (percent)
HIV + (n = 52) HIV- (n = 105) P-value
Treatment success+ 36 (69.2) 100 (95.2) <0.001
Treatment completed^ 6 (11.5) 5 (4.8)
Cure 30 (57.7) 95 (90.5)
Treatment failure 2 (3.8) 2 (1.9)
Lost to follow-up 8 (15.4) 2 (1.9)
Death 6 (11.5) 1 (1.0)
+ Sum of cure and treatment completed.
^ These patients were either diagnosed by bronchoscopy and smear positive
aspirate, or unable to produce sputum to provide evidence of sputum
conversion and therefore cure, but had clinical and radiological resolution at
end of treatment.








Treatment success+ 41 (40.2) 79 (72.5) P < 0.001
Treatment completed 37 (36.3) 38 (34.9)
Cure 4 (3.9) 41 (37.6)
Treatment success
[excluding those lost to
follow up and defaulters]^
41 (53.2) 79 (89.8) P < 0.001
Treatment failure 8 (7.8) 4 (3.7)
Relapse 5 (4.9) 2 (1.8)
Default 4 (3.9) 0
Lost to follow-up 21 (20.6) 21 (19.3)
Death 22 (21.6) 3 (2.8) P < 0.001
Treatment modified 1 (1.0) 0
* Includes patients completing 24 months follow-up and those being labelled
as death, lost to follow-up, failure and relapse – i.e. does not include patients
still under active follow-up.
+ Sum of cure and treatment completed.
^ In this outcome, the 'default' and 'lost to follow up' groups have been
removed from the cohort, so that for HIV + n = 77, and for HIV- n = 88.
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Uni- and multivariate analysis of independent risk fac-
tors for mortality in the HIV-positive group found only
baseline CD4 cell count to be significant. Patients with
CD4 cell count of less than 100 cells/mm3 had an odds
ratio of 8 · 43 for mortality (p = 0 · 013; CI: 1 · 58-44 · 95).
Adverse events
Table 9 details adverse events in the two groups while
on treatment (totals and selected events). A similar
number of non-serious adverse events were encountered
in both groups (p = 0.851), while significantly more ser-
ious adverse events were observed in the HIV-positive
patients (p < 0.001). Anaemia prompted switch from
zidovudine to stavudine, while drug induced hepatoto-
xicity was treated by temporary ATT modification. Be-
sides deaths and IRIS (see below), no other serious
adverse event was observed.
Immune reconstitution inflammatory syndrome (IRIS)
occurred in 14 patients at a median of 76.5 days after
commencing ART; all were mild and did not require
discontinuation of treatment. There was a significant
increase in median CD4 cell count (p = 0 · 001) and decrease
in mean log plasma viral load (p < 0 · 0001) between pre-
IRIS and post-IRIS values.
In total, 22 HIV-positive and 3 HIV-negative patients
died. Of the HIV-positive deaths, 5 were within the first
2 months, a further 8 on treatment, and 9 were during
follow-up; the median time of death was 5.5 months
after enrolment. Four deaths (three HIV-positive, one
HIV-negative) were confirmed as due to TB. Insufficient
details were available for the remaining patients to deter-
mine causality, as they died at home or at a different
hospital.
Discussion
The proportion of HIV-negative patients achieving tre-
atment success was much higher than HIV-positive
patients: at the end of treatment, 93.5% versus 76.7%
(P < 0.001); at the end of treatment in those with sputum
positive pulmonary TB, 95.2% versus 69.2% (P < 0.001);
and at 24 months follow up excluding those lost to fol-
low up, 89.8% versus 53.2% (P < 0.001). Multivariate ana-
lysis did not reveal any independent risk factor for not
achieving treatment success within each group.
Higher treatment success in HIV-negative and higher
mortality in HIV-positive patients in the present study
are in agreement with previous studies [8,13]. Indeed,
the end of treatment mortality rate in the present study’s
co-infected patients (8 · 1%) is lower than most previous
figures – Khan et al’s meta-analysis quotes 15% [16]. In
many studies, no patients received ART (unlike universal
highly active ART in the present one), which may ex-
plain higher mortality. Abdool Karim et al. found in
2010 that ART during ATT reduced mortality by 56%,
to just 5.4% in median 12.1 months follow-up [2]. Inter-
estingly, recent studies without concurrent ART quote
10 · 4% [12] and 10 · 9% [18], which suggests the fall in
mortality may be due in part to other improvements in
HIV/TB care.
Mortality was largely after the intensive phase of ATT,
with half of the HIV positive patients dying in the
follow-up stage, which has been suggested previously
[2,11,12]. Only four deaths in the present study were at-
tributable to TB. These observations may implicate
HIV/AIDS as a more important factor for mortality than
TB, though paucity of death causation data means this
assumption is difficult to make. However, lower nadir
CD4 counts in patients who subsequently died support
this hypothesis, which is often related to delayed presen-
tation, described previously at our Centre [20].
Multivariate analysis revealed those with CD4 count
< 100 cells/mm3 had 8-fold higher risk of dying. This has
been shown previously [2,12], and suggests that immuno-
logical effects of HIV need close attention in TB-HIV co-
infection, with early ART commencement being advocated
by most bodies [2,3]. It may also mean that this subgroup
may be considered for targeted interventions such as daily
therapy, extended duration or otherwise.
Treatment failure and relapse rates were not signifi-
cantly different in HIV-positive and HIV-negative pa-
tients. Previous publications are divided on these with
regards to HIV status [5]. Most studies have shown simi-
lar failure rates regardless of HIV status [13,27], which is





















IRIS* 14 (9.3%) 0 14 (4.6%)
Anaemia (new on treatment)* 9 (6.0%) 0 9 (3.0%)
Drug-induced hepatotoxicity* 5 (3.3%) 0 5 (1.6%)
Isoniazid-induced psychosis* 1 (0.7%) 0 1 (0.3%)
Stevens-Johnson syndrome* 1 (0.7%) 0 1 (0.3%)
Peripheral neuropathy* 2 (1.3%) 0 2 (0.7%)
Haemoptysis* 0 6 (3.9%) 0
Itch 9 (6.0%) 2 (1.3%) 11 (3.6%)



















* Classified as serious adverse events.
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observed in the present study. Some studies report re-
lapse being more common in HIV co-infection [11,28].
Pooled data show a higher relapse rate (12% PYO) in
HIV-positive individuals than reported in this study (3 ·
48% PYO) [16]. Spoligotyping in HIV-positive patients
revealed three out of four having exogenous reinfection
with TB – reports of the proportion being reinfected
vary, however, the number of relapses are too small in
this case to make any conclusions. This may reflect inad-
equate airborne infection control measures.
Sputum smear and culture conversion rates at 2 months
were found to be similar regardless of HIV status. The
2-month culture conversion rate for HIV-positive individ-
uals (85 · 3%) was in accordance with earlier reports, with
a range of 74-95% being quoted [11,17,18].
Extension of ATT of 1–3 months was required in 35
of the HIV-positive patients, but only 13 in the HIV-
negative group (median 1 month). A trial comparing 6
with 9 months thrice weekly ATT demonstrated lower
bacteriological recurrence with 9 months treatment, but
found no other benefits [12]. Hence it is unclear whether
longer treatment would be beneficial.
HIV-infected patients were started on ART a median
of 30 days after ATT, with good immunological and
virological response. This is representative of present
care of such patients according to recent WHO guid-
ance stating all people with HIV-TB co-infection should
be started on ART early in the ATT course [3]. It corre-
lates well with other studies looking at outcomes of
HIV-TB co-infection with early/concurrent ART [2,29].
With regards to safety, a similar frequency of non-
serious adverse events was found in each group; though
this seems higher than in several studies, reporting up to
37% of patients experiencing any event [12,13,17]. Such
events were all self-limiting or easily treated, and may
reflect the close monitoring in this study. The signifi-
cantly higher incidence of serious adverse events in the
HIV-positive group was mostly made up of deaths and
HIV-specific events. The 29.3% figure observed is similar
to that observed in the 'integrated therapy' group of
Abdool Karim et al's recent study [2]. In addition, fin-
dings of the present study are similar to previous reports
of low hepatotoxicity figures with thrice weekly treat-
ment regimens [30].
The study depicts an up-to-date comparison of outcomes
of thrice weekly six-month ATT in HIV-positive and -
negative individuals. Strengths include: supplementation of
currently lacking follow-up data on outcomes of intermit-
tent ATT in HIV co-infected patients, especially in terms of
relapse rates and late mortality; the real-life situation has
been studied, with inclusion of smear-negative and
extrapulmonary patients, concurrent ART, and preservation
of the national TB programme’s treatment protocol; and
surveillance results, including sputum culture conversion
rate and post-ATT follow-up, in Indian patients (currently
absent from national programme reports).
Limitations of this study include: 1) Lack of routine
DST in order to screen for drug resistance: this is not
universally recommended for patients with a new TB
diagnosis by Indian or WHO guidelines [3,24], but is in-
creasingly being used in research settings [5,12]. 2) The
high attrition rate, especially in the HIV-positive group
and after initial treatment, may have impacted on com-
pleteness of follow-up data. This is a common problem
in resource-limited settings, as highlighted previously at
this institute’s ART clinic [20]. 3) A significant propor-
tion of patients were not definitive (bacteriologically
confirmed) cases of TB, despite thorough investigation
to exclude other diagnoses and most having response to
treatment. 4) The study was observational, with resulting
lack of control of confounding factors, evidenced by
baseline heterogeneity. 5) As numbers of relapse and
failure cases were small, it is difficult to judge differences
between the two groups with confidence in this respect.
Conclusions
Intermittent ATT is desirable in developing country set-
tings to maintain direct observation with minimal strain
on stretched health systems. However it has been poorly
studied [31]. The present study shows excellent out-
comes and safety of thrice-weekly ATT in HIV-negative
individuals, confirming its adequacy in these patients
[3], though acquired rifampicin resistance may be pro-
moted, which needs detailed study [3,5,12]. Outcomes in
HIV co-infection do not seem to be as good, with lower
treatment success and higher mortality being observed,
though with adequate safety. This should prompt further
focussed study on treatment options for these patients,
such as a trial starting at this institute examining out-
comes of daily versus thrice-weekly therapy. National
programme coordinators should re-visit guidelines, and
investigate whether therapy changes in HIV co-infection
should be universal, as recommended by the WHO [3],
or in specific subgroups, such as those with low CD4
counts, to balance attempts to reduce morbidity and
mortality in TB-HIV co-infection with awareness of re-
source constraints.
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